PXD025421

PXD025421 is an original dataset announced via ProteomeXchange.

Title	Synthetic bacterial vesicles combined with tumor exosomes as cancer immunotherapy
Description	Bacterial outer membrane vesicles (OMV) have gained attention as a promising new cancer vaccine platform for efficiently provoking immune responses. However, OMV induce severe toxicity by activating the innate immune system. In this study, we applied a simple isolation approach to produce artificial OMV that we have named Synthetic Bacterial Vesicles (SyBV) that do not induce a severe toxic response. We also explored the potential of SyBV as an immunotherapy combined with tumor exosomes to induce anti-tumor immunity. Bacterial SyBV were produced with high yield by a protocol including lysozyme and high pH treatment, resulting in pure vesicles with very few cytosolic components and no RNA or DNA. These SyBV did not cause systemic pro-inflammatory cytokine responses in mice compared to naturally released OMV. However, SyBV and OMV were similarly effective in activation of mouse bone marrow-derived dendritic cells. Co-immunization with SyBV and melanoma tumor tissue exosomes elicited tumor regression in melanoma-bearing mice through Th-1 type T cell immunity and balanced antibody production. Also, the immunotherapeutic effect of SyBV was synergistically enhanced by anti-PD-1 inhibitor. Moreover, SyBV displayed significantly greater adjuvant activity than other classical adjuvants. Taken together, these results demonstrate a safe and efficient strategy for eliciting specific anti-tumor responses using immunotherapeutic bacterial SyBV.
HostingRepository	PRIDE
AnnounceDate	2026-07-06
AnnouncementXML	Submission_2026-07-06_04:15:38.170.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Proteomics Core Facility
SpeciesList	scientific name: Escherichia coli; NCBI TaxID: NEWT:562;
ModificationList	No PTMs are included in the dataset
Instrument	Orbitrap Fusion

Revision	Datetime	Status	ChangeLog Entry
0	2021-04-15 02:47:57	ID requested
⏵ 1	2026-07-06 04:15:38	announced

10.1002/jev2.12120;

Park KS, Svennerholm K, Crescitelli R, L, ä, sser C, Gribonika I, L, ö, tvall J, Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy. J Extracell Vesicles, 10(9):e12120(2021) [pubmed]

submitter keyword: outer membrane vesicles, cancer immunotherapy,Synthetic bacterial vesicles

Jan Lötvall
contact affiliation	Krefting Research Centre, Institute of Medicine, University of Gothenburg, Sweden
contact email	jan.lotvall@gu.se
lab head
Proteomics Core Facility
contact affiliation	SAMBIO Core Facilities, Sahgrenska Academy, University of Gothenburg
contact email	gupcf@outlook.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/07/PXD025421

PRIDE project URI

• PRIDE
  1. PXD025421
     1. Label: PRIDE project
     2. Name: Synthetic bacterial vesicles combined with tumor exosomes as cancer immunotherapy